PERSEVERE- A Trial to Evaluate AMDS in Acute DeBakey Type I Dissection
← catalyst calendarSponsored by Artivion Inc. (industry) · AORT — their whole pipeline →. With Syneos Health.
Phase
Not applicable
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
115actual
Sites
25
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-05-27 | actual | When the study began enrolling |
| Primary completion | 2023-12-11 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-12-06 | estimated | The whole study's end, after follow-up |
| First posted | 2022-01-03 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-01-15 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Acute Aortic Dissection
Intervention
- Device: AMDS
Primary outcomes
what the primary-completion date above is the date OFPrimary Endpoint to Assess Incidence of Major Adverse Events
measured Through 30 days
Primary Endpoint to Assess Distal Anastomotic New Entry (DANE) tears
measured Through 30 days
Publications
- PMID 39116932 — reports results
- PMID 41238072 — linked by the registry
- PMID 40586922 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · AORT's whole pipeline · Catalyst calendar · Every registered study · What changed